Large gap with delayed quotes
Analysis date: 13.10.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 29.09.2026.
Quality
Weak
Weak
Two stars since 29.09.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 11.09.2026 at a price of 54.21.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 01.09.2026.
4wk Rel Perf
-23.76%
-23.76%
The four-week dividend-adjusted underperformance versus SP500 is 23.76%.
Risk
High
High
The stock has been on the high-sensitivity level since 10.07.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.16%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.34%.
Mkt Cap in $bn
7.26
7.26
With a market capitalization between $2 & $8bn, IONIS PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
2.32
2.32
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
12.21
12.21
The estimated PE is for the year 2029.
LT Growth
28.36%
28.36%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
31
31
For 1% of index variation, the stock varies on average by 0.31%.
Correlation
0.10
0.10
Stock movements are totally independent of index variations.
Value at Risk
10.25
10.25
The value at risk is estimated at USD 10.25. The risk is therefore 24.18%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.05.2008
02.05.2008